Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Vaccines Acquires Suzhou Manufacturing Facility from Harbour BioMed

publication date: Nov 15, 2022

WuXi Vaccines, a division of WuXi Biologics, will acquire an 8,500-square-meter facility Suzhou manufacturing facility from Harbour BioMed. The plant, WuXi Vaccines' first standalone vaccine development and GMP manufacturing site in China, will be renovated to provide vaccine development and GMP manufacturing services. The terms of the agreement were not disclosed. WuXi Vaccines has also built a $240 million manufacturing facility that is near completion in Dundalk, Ireland. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital